The addition of vemurafenib to irinotecan and cetuximab improved progression-free survival (PFS) and tumor response in BRAF-MT CRC that was previously treated with one or two regimens of palliative chemotherapy in another prospective randomized phase II study [12,13]. Here, BRAF is linked to colorectal carcinoma.